|
EP2655409A4
(en)
|
2010-12-22 |
2015-07-01 |
Univ Leland Stanford Junior |
SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
|
|
WO2013176915A1
(en)
*
|
2012-05-25 |
2013-11-28 |
Roman Galetto |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
EP2934532B1
(en)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
KR102064230B1
(ko)
|
2013-02-15 |
2020-01-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
키메라 항원 수용체 및 이의 이용 방법
|
|
WO2014151960A2
(en)
|
2013-03-14 |
2014-09-25 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling t cell proliferation
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2956667A1
(en)
*
|
2013-07-29 |
2015-02-05 |
Bluebird Bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
WO2015042707A1
(en)
|
2013-09-24 |
2015-04-02 |
Medicenna Therapeutics Pte Ltd |
Interleukin-2 fusion proteins and uses thereof
|
|
HUE050156T2
(hu)
|
2013-12-17 |
2020-11-30 |
Genentech Inc |
Anti-CD3 antitestek és alkalmazási eljárások
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
ES2701846T3
(es)
*
|
2014-01-14 |
2019-02-26 |
Cellectis |
Receptor de antígeno quimérico que usa dominios de reconocimiento de antígenos derivados de pez cartilaginoso
|
|
CN111849912B
(zh)
|
2014-02-14 |
2024-03-15 |
贝里坤制药股份有限公司 |
用诱导型嵌合多肽活化t细胞的方法
|
|
EP3119425B1
(en)
*
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
EP4406610A3
(en)
|
2014-04-07 |
2024-10-30 |
Novartis AG |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
|
MX382541B
(es)
|
2014-04-23 |
2025-03-13 |
Juno Therapeutics Inc |
Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
|
|
CN106659757B
(zh)
|
2014-04-24 |
2022-01-28 |
利兰斯坦福初级大学董事会 |
白介素2的超级激动剂、部分激动剂和拮抗剂
|
|
SG11201609118RA
(en)
|
2014-05-15 |
2016-11-29 |
Univ Singapore |
Modified natural killer cells and uses thereof
|
|
EP3685842B1
(en)
*
|
2014-06-06 |
2022-08-31 |
Memorial Sloan-Kettering Cancer Center |
Mesothelin-targeted chimeric antigen receptors and uses thereof
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
EP3174546B1
(en)
|
2014-07-31 |
2019-10-30 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
DK4074735T3
(da)
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
US10888608B2
(en)
|
2014-09-02 |
2021-01-12 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
|
|
EP3699188A1
(en)
|
2014-09-04 |
2020-08-26 |
Cellectis |
5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
|
JP6839074B2
(ja)
*
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
JP2017532325A
(ja)
*
|
2014-10-03 |
2017-11-02 |
イエール ユニバーシティ |
抗癌療法のための自然免疫系の改変
|
|
EP3204491A1
(en)
*
|
2014-10-07 |
2017-08-16 |
Cellectis |
Method for modulating car-induced immune cells activity
|
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
EP3025719B1
(en)
|
2014-11-26 |
2018-09-26 |
Miltenyi Biotec GmbH |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
BR112017011771A2
(pt)
*
|
2014-12-02 |
2018-07-10 |
Prospect Chartercare Rwmc Llc |
métodos e composições para o tratamento de câncer
|
|
SI3227339T1
(sl)
|
2014-12-05 |
2022-02-28 |
Memorial Sloan-Kettering Cancer Center |
Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba
|
|
EP3227324A4
(en)
|
2014-12-05 |
2018-08-29 |
Memorial Sloan Kettering Cancer Center |
Antibodies targeting g-protein coupled receptor and methods of use
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
EP3240805B1
(en)
|
2014-12-15 |
2024-11-27 |
The Regents of the University of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
US20160175359A1
(en)
*
|
2014-12-15 |
2016-06-23 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlled activation or elimination of therapeutic cells
|
|
WO2016098078A2
(en)
*
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
JP6718450B2
(ja)
*
|
2014-12-19 |
2020-07-08 |
イーティーエッチ チューリッヒ |
キメラ抗原受容体及びその使用方法
|
|
ES2743188T3
(es)
|
2014-12-24 |
2020-02-18 |
Aadigen Llc |
Péptidos y nanopartículas para el suministro intracelular de moléculas
|
|
KR20250075716A
(ko)
|
2014-12-29 |
2025-05-28 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
|
GB201501936D0
(en)
*
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
GB201503133D0
(en)
|
2015-02-24 |
2015-04-08 |
Ucl Business Plc And Syncona Partners Llp |
Chimeric protein
|
|
CA2977106A1
(en)
|
2015-02-27 |
2016-09-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
US10195272B2
(en)
|
2015-03-02 |
2019-02-05 |
The Nemours Foundation |
Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
|
|
GB201504840D0
(en)
|
2015-03-23 |
2015-05-06 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CA2981304C
(en)
*
|
2015-04-02 |
2024-01-02 |
Memorial Sloan Kettering Cancer Center |
Tnfrsf14/hvem proteins and methods of use thereof
|
|
HUE059218T2
(hu)
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
WO2016168773A2
(en)
*
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
CA2985816A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
|
PT3298033T
(pt)
|
2015-05-18 |
2020-09-22 |
Tcr2 Therapeutics Inc |
Composições e utilizações médicas para reprogramação de tcr utilizando proteínas de fusão
|
|
SG10201913682QA
(en)
|
2015-06-25 |
2020-03-30 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
SG10201912978PA
(en)
|
2015-07-21 |
2020-02-27 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
EP3575403A1
(en)
*
|
2015-08-05 |
2019-12-04 |
Yoo Young Pharm Co., Ltd. |
Chimeric antigen receptor, and t cells in which chimeric antigen receptor is expressed
|
|
CN108350062B
(zh)
|
2015-08-06 |
2022-10-14 |
达纳-法伯癌症研究所股份有限公司 |
靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
|
|
EP3331913A1
(en)
*
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
AU2016313082B2
(en)
|
2015-08-24 |
2022-03-31 |
Cellectis |
Chimeric antigen receptors with integrated controllable functions
|
|
CN108138362B
(zh)
|
2015-09-01 |
2022-03-29 |
加利福尼亚大学董事会 |
模块化多肽文库以及其制备和使用方法
|
|
EP3344996A2
(en)
|
2015-09-03 |
2018-07-11 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
CN109310744A
(zh)
|
2015-09-23 |
2019-02-05 |
赛通免疫有限责任公司 |
用于免疫治疗的flt3定向car细胞
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017087708A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
WO2017087723A1
(en)
*
|
2015-11-19 |
2017-05-26 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
US11530252B2
(en)
|
2015-11-23 |
2022-12-20 |
Trustees Of Boston University |
Methods and compositions relating to chimeric antigen receptors
|
|
SG11201804957VA
(en)
|
2015-12-16 |
2018-07-30 |
Gritstone Oncology Inc |
Neoantigen identification, manufacture, and use
|
|
EP3184548A1
(en)
|
2015-12-23 |
2017-06-28 |
Miltenyi Biotec GmbH |
Chimeric antigen receptor with cytokine receptor activating or blocking domain
|
|
EP3397755B1
(en)
|
2015-12-28 |
2024-11-06 |
Novartis AG |
Methods of making chimeric antigen receptor -expressing cells
|
|
EP3399991A4
(en)
*
|
2016-01-08 |
2019-08-07 |
The Regents of The University of California |
REQUIRES ACTIVE HETERODIMER POLYPEPTIDES AND METHOD FOR USE THEREOF
|
|
ES2875747T3
(es)
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
BR112018013679A2
(pt)
|
2016-01-11 |
2019-01-22 |
Univ Leland Stanford Junior |
proteínas quiméricas e métodos de regulação de expressão gênica
|
|
CN105567640A
(zh)
*
|
2016-01-27 |
2016-05-11 |
苏州佰通生物科技有限公司 |
一种嵌合抗原受体脂肪干细胞及其制备方法
|
|
GB201602563D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
GB201602571D0
(en)
*
|
2016-02-12 |
2016-03-30 |
Autolus Ltd |
Signalling system
|
|
US10871490B2
(en)
|
2016-02-29 |
2020-12-22 |
Multenyi Biotec, gmbH |
Assay for detection of chimeric antigen receptor T cells
|
|
CN109715207B
(zh)
*
|
2016-03-29 |
2023-03-31 |
南加利福尼亚大学 |
靶向癌症的嵌合抗原受体
|
|
US11768203B2
(en)
|
2016-03-31 |
2023-09-26 |
University Of Southern California |
Highly sensitive and specific luciferase based reporter assay for antigen detection
|
|
PE20200400A1
(es)
|
2016-04-01 |
2020-02-26 |
Kite Pharma Inc |
Receptores quimericos y metodos de uso de los mismos
|
|
MA44507A
(fr)
|
2016-04-01 |
2019-02-06 |
Amgen Inc |
Récepteurs chimères de flt3 et leurs procédés d'utilisation
|
|
NZ746700A
(en)
|
2016-04-01 |
2023-04-28 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
|
SG10201912489QA
(en)
|
2016-04-01 |
2020-02-27 |
Kite Pharma Inc |
Chimeric antigen and t cell receptors and methods of use
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
US11976116B2
(en)
|
2016-04-14 |
2024-05-07 |
2Seventy Bio, Inc. |
Salvage chimeric antigen receptor systems
|
|
EP3443075B1
(en)
|
2016-04-15 |
2022-09-28 |
Memorial Sloan Kettering Cancer Center |
Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
|
|
TWI851939B
(zh)
|
2016-05-13 |
2024-08-11 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
EP4353750A3
(en)
|
2016-06-24 |
2024-07-24 |
iCell Gene Therapeutics LLC |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
US11384156B2
(en)
|
2016-07-25 |
2022-07-12 |
The Nemours Foundation |
Adoptive T-cell therapy using EMPD-specific chimeric antigen receptors for treating IgE-mediated allergic diseases
|
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
AU2017307610B2
(en)
|
2016-08-04 |
2023-10-05 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
CN109789164B
(zh)
*
|
2016-08-30 |
2023-04-28 |
亘喜生物科技（上海）有限公司 |
具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN107793483B
(zh)
*
|
2016-09-06 |
2019-08-23 |
伍志强 |
嵌合抗原受体及其基因和重组表达载体、carmsln-nkt细胞及其制备方法和应用
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
JP6698854B2
(ja)
*
|
2016-09-16 |
2020-05-27 |
キッセイ薬品工業株式会社 |
遺伝子改変細胞及びその作製方法
|
|
AU2017338846B2
(en)
*
|
2016-10-04 |
2020-09-24 |
Precision Biosciences, Inc. |
Co-stimulatory domains for use in genetically-modified cells
|
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
EP4092049A1
(en)
*
|
2016-10-20 |
2022-11-23 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN107058315B
(zh)
*
|
2016-12-08 |
2019-11-08 |
上海优卡迪生物医药科技有限公司 |
敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用
|
|
CA3045667A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
AU2018207300B2
(en)
*
|
2017-01-10 |
2023-08-24 |
The General Hospital Corporation |
T cells expressing a chimeric antigen receptor
|
|
CN107573419A
(zh)
*
|
2017-01-24 |
2018-01-12 |
深圳市体内生物医药科技有限公司 |
一种增强t细胞抗肿瘤活性的核酸分子
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
EP3580212A4
(en)
*
|
2017-02-08 |
2021-03-17 |
Dana Farber Cancer Institute, Inc. |
REGULATION OF CHEMERIC ANTIGEN RECEPTORS
|
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための組成物および方法
|
|
WO2018161017A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Obsidian Therapeutics, Inc. |
Cd19 compositions and methods for immunotherapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
CN110636851B
(zh)
|
2017-03-27 |
2023-11-03 |
新加坡国立大学 |
截短的nkg2d嵌合受体及其在自然杀伤细胞免疫疗法中的用途
|
|
RU2019128544A
(ru)
|
2017-03-27 |
2021-04-28 |
Нэшнл Юниверсити Оф Сингапур |
Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
|
|
JOP20180027A1
(ar)
|
2017-03-28 |
2019-01-30 |
Cell Design Labs Inc |
بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
CN118161496A
(zh)
|
2017-03-31 |
2024-06-11 |
小利兰·斯坦福大学托管委员会 |
通过抑制或调节t细胞受体信号传导来治疗t细胞耗竭的方法
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
EP3610266A4
(en)
|
2017-04-12 |
2021-04-21 |
Massachusetts Eye and Ear Infirmary |
TUMOR SIGNATURE FOR METASTASIS, COMPOSITIONS OF MATERIAL AND THEIR METHODS OF USE
|
|
CA3060443A1
(en)
|
2017-04-19 |
2018-10-25 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
AU2018265242B2
(en)
*
|
2017-05-12 |
2024-01-18 |
Cellectis |
Protease based switch chimeric antigen receptors for safer cell immunotherapy
|
|
AU2018270078A1
(en)
*
|
2017-05-15 |
2019-11-07 |
Autolus Limited |
A cell comprising a chimeric antigen receptor (CAR)
|
|
CN107141356B
(zh)
*
|
2017-06-07 |
2020-03-13 |
胜武（北京）生物科技有限公司 |
一种光诱导二聚体型嵌合抗原受体
|
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
|
US11325957B2
(en)
|
2017-06-19 |
2022-05-10 |
Cell Design Labs, Inc. |
Methods and compositions for reducing the immunogenicity of chimeric notch receptors
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
JP2020524512A
(ja)
|
2017-06-21 |
2020-08-20 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
|
|
WO2019014581A1
(en)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
|
|
CN107446937B
(zh)
*
|
2017-09-05 |
2020-12-25 |
深圳华云生物技术有限公司 |
嵌合抗原受体及其表达基因、光控调节的嵌合抗原受体修饰的t细胞及其应用
|
|
EP3679065A4
(en)
*
|
2017-09-06 |
2021-05-19 |
California Institute of Technology |
SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR)
|
|
CN109504697A
(zh)
*
|
2017-09-15 |
2019-03-22 |
上海恒润达生生物科技有限公司 |
一种靶向人源化mesothelin的嵌合抗原受体的方法和用途
|
|
AU2018335266A1
(en)
*
|
2017-09-22 |
2020-02-06 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chimeric antigen receptors with enhanced NFκB signaling
|
|
CN109553686A
(zh)
*
|
2017-09-26 |
2019-04-02 |
南京安吉生物科技有限公司 |
一种新型可调控的双嵌合抗原受体t细胞及其构建方法和应用
|
|
US12065498B2
(en)
|
2017-09-29 |
2024-08-20 |
Cell Design Labs, Inc. |
Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same
|
|
GB201715918D0
(en)
*
|
2017-09-29 |
2017-11-15 |
Tc Biopharm Ltd |
Modified CAR-T
|
|
US12043870B2
(en)
|
2017-10-02 |
2024-07-23 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
MX2020004229A
(es)
|
2017-10-25 |
2020-07-22 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710471A1
(en)
|
2017-11-16 |
2020-09-23 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
KR20200090855A
(ko)
|
2017-11-22 |
2020-07-29 |
그릿스톤 온콜로지, 인코포레이티드 |
신생항원에 대한 접합 에피토프 제시 감소
|
|
EP3724339A2
(en)
|
2017-12-14 |
2020-10-21 |
Celyad S.A. |
Pooling signaling and costimulatory domains in flexible car design
|
|
WO2019118895A1
(en)
*
|
2017-12-14 |
2019-06-20 |
Bluebird Bio, Inc. |
Daric interleukin receptors
|
|
EP3502130A1
(en)
|
2017-12-20 |
2019-06-26 |
St. Anna Kinderkrebsforschung |
Ligand regulated protein-protein interaction system
|
|
JP2021506329A
(ja)
|
2017-12-20 |
2021-02-22 |
ザンクト アンナ キンダークレプスフォルシュング |
リガンド制御したタンパク質−タンパク質相互作用システム
|
|
JP7467339B2
(ja)
|
2017-12-22 |
2024-04-15 |
フェイト セラピューティクス，インコーポレイテッド |
強化された免疫エフェクター細胞およびその使用
|
|
US20190194617A1
(en)
*
|
2017-12-22 |
2019-06-27 |
Cell Design Labs, Inc. |
Single- and multi-chain chimeric antigen receptors
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
EP3735425A1
(en)
|
2018-01-04 |
2020-11-11 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for bdca2 antigen
|
|
CA3089319A1
(en)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for car t cells
|
|
CN108017717B
(zh)
*
|
2018-01-24 |
2019-08-16 |
首都医科大学宣武医院 |
一种用于体外高效定向扩增的嵌合抗原受体及其应用
|
|
BR112020015884A2
(pt)
|
2018-02-06 |
2020-12-08 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Receptores de antígeno quimérico (cars) específicos de fluoresceína exibindo a função de célula t ótima contra os tumores marcados por fl-ple
|
|
CR20200391A
(es)
|
2018-02-08 |
2020-10-19 |
Genentech Inc |
Moléculas biespecíficas de unión al antígeno y métodos de uso
|
|
CA3089170A1
(en)
|
2018-02-09 |
2019-08-15 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
WO2019157496A1
(en)
*
|
2018-02-12 |
2019-08-15 |
University Of Florida Researchfoundation, Inc. |
Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
|
|
CN112534044A
(zh)
|
2018-02-16 |
2021-03-19 |
凯德药业股份有限公司 |
经修饰的多能干细胞及制备和使用方法
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
US12240870B2
(en)
|
2018-02-23 |
2025-03-04 |
Purdue Research Foundation |
Sequencing method for CAR T cell therapy
|
|
KR20200127001A
(ko)
|
2018-02-27 |
2020-11-09 |
그릿스톤 온콜로지, 인코포레이티드 |
범-대립유전자 모델을 갖는 신생항원 동정
|
|
WO2019168923A1
(en)
|
2018-03-01 |
2019-09-06 |
University Of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
WO2019166453A1
(en)
*
|
2018-03-01 |
2019-09-06 |
F. Hoffmann-La Roche Ag |
Specificity assay for novel target antigen binding moieties
|
|
EP3743446A1
(en)
*
|
2018-03-12 |
2020-12-02 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
EP3765491B1
(en)
*
|
2018-03-14 |
2024-04-03 |
Medigene Immunotherapies GmbH |
Inducible t cell receptors and uses thereof
|
|
KR102817092B1
(ko)
|
2018-03-29 |
2025-06-09 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 면역 효과기 세포 및 이의 용도
|
|
SG11202008976YA
(en)
|
2018-04-02 |
2020-10-29 |
Nat Univ Singapore |
Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
|
|
US12090170B2
(en)
|
2018-04-06 |
2024-09-17 |
The Regents Of The University Of California |
Methods of treating glioblastomas
|
|
EP3773632A4
(en)
|
2018-04-06 |
2022-05-18 |
The Regents of The University of California |
Methods of treating egfrviii expressing glioblastomas
|
|
AU2019247830A1
(en)
*
|
2018-04-06 |
2020-10-22 |
The Regents Of The University Of California |
Trans-antigen targeting in heterogeneous cancers and methods of use thereof
|
|
AU2019251473A1
(en)
|
2018-04-10 |
2020-10-22 |
Amgen Inc. |
Chimeric receptors to DLL3 and methods of use thereof
|
|
CN108410908B
(zh)
*
|
2018-04-12 |
2021-08-03 |
吉林大学 |
一种利用植物激素ga及小分子物质pac调节细胞通路的方法
|
|
EP3774866A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Ludwig Institute for Cancer Research Ltd |
Heterodimeric inactivatable chimeric antigen receptors
|
|
JP7527641B2
(ja)
|
2018-04-18 |
2024-08-05 |
アブクロン・インコーポレイテッド |
スイッチ分子及びスイッチャブルキメラ抗原受容体
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
CN108715616A
(zh)
*
|
2018-04-27 |
2018-10-30 |
上海恒润达生生物科技有限公司 |
靶向人源化间皮素的嵌合抗原受体方法和用途
|
|
US12473342B2
(en)
|
2018-04-27 |
2025-11-18 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
|
|
SG11202007874XA
(en)
|
2018-04-27 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Rapamycin resistant cells
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
IL321548A
(en)
*
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
CN112533943B
(zh)
|
2018-06-01 |
2024-03-05 |
利兰斯坦福初级大学董事会 |
Il-13/il-4超级因子：免疫细胞靶向性构建体及其使用方法
|
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
CN110577604A
(zh)
*
|
2018-06-07 |
2019-12-17 |
亘喜生物科技（上海）有限公司 |
携带gitr共刺激信号靶向egfr的嵌合抗原受体t细胞
|
|
MY208825A
(en)
|
2018-06-13 |
2025-05-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2019246563A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
CN110669138A
(zh)
*
|
2018-07-02 |
2020-01-10 |
中国药科大学 |
一种双嵌合抗原受体、t细胞及其构建方法与应用
|
|
CN112513270B
(zh)
|
2018-07-13 |
2025-02-25 |
加利福尼亚大学董事会 |
基于逆转录转座子的递送媒介物及其使用方法
|
|
US20210277148A1
(en)
|
2018-07-18 |
2021-09-09 |
Amgen Inc. |
Chimeric receptors to steap1 and methods of use thereof
|
|
MX2021001523A
(es)
|
2018-08-09 |
2021-05-27 |
Juno Therapeutics Inc |
Procesos para generar células modificadas y composiciones de las mismas.
|
|
CA3109236A1
(en)
|
2018-08-13 |
2020-02-20 |
Aarhus Universitet |
Genetically altered lysm receptors with altered agonist specificity and affinity
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
US20210171909A1
(en)
|
2018-08-31 |
2021-06-10 |
Novartis Ag |
Methods of making chimeric antigen receptor?expressing cells
|
|
DK3844267T3
(da)
|
2018-08-31 |
2025-09-22 |
Novartis Ag |
Fremgangsmåder til fremstilling af kimære antigenreceptorudtrykkende celler
|
|
CN112823166B
(zh)
*
|
2018-09-07 |
2025-01-24 |
生物蛋白有限公司 |
用于修饰的t细胞的条件活性嵌合抗原受体
|
|
EP3856779A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd22 chimeric antigen receptor (car) therapies
|
|
EP3856782A1
(en)
|
2018-09-28 |
2021-08-04 |
Novartis AG |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
EP3632460A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
WO2020070290A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3860642A1
(en)
*
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816839D0
(en)
*
|
2018-10-16 |
2018-11-28 |
Glaxosmithkline Ip Dev Ltd |
Novel control switch
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
CA3121128A1
(en)
|
2018-12-02 |
2020-06-11 |
Fate Therapeutics, Inc. |
Immunotherapies using enhanced ipsc derived effector cells
|
|
EP3891185A2
(en)
|
2018-12-05 |
2021-10-13 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
|
WO2020118305A1
(en)
*
|
2018-12-07 |
2020-06-11 |
The Trustees Of Columbia University In The City Of New York |
Muc4 car-t cells for treating cancer
|
|
BR112021012172A2
(pt)
|
2018-12-12 |
2021-08-31 |
Kite Pharma, Inc. |
Receptores de antígenos quiméricos e de célula t e métodos de uso
|
|
WO2020123947A1
(en)
|
2018-12-14 |
2020-06-18 |
Bluebird Bio, Inc. |
Dimerizing agent regulated immunoreceptor complexes
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
WO2020141106A1
(en)
|
2019-01-03 |
2020-07-09 |
Kemijski Institut |
Engineered externally regulated artificial transcription regulatory system based on engineered nfat
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
WO2020152197A1
(en)
|
2019-01-23 |
2020-07-30 |
Miltenyi Biotec B.V. & Co. KG |
A combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
|
|
TW202045547A
(zh)
|
2019-03-01 |
2020-12-16 |
美商艾洛基因醫療公司 |
靶向ｄｌｌ３的嵌合抗原受體和結合劑
|
|
SG11202109057XA
(en)
*
|
2019-03-05 |
2021-09-29 |
Nkarta Inc |
Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US20220193137A1
(en)
|
2019-04-04 |
2022-06-23 |
Umc Utrecht Holding B.V. |
Modified immune receptor constructs
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN114007654A
(zh)
|
2019-04-17 |
2022-02-01 |
阿迪根有限公司 |
用于分子的细胞内递送的肽和纳米颗粒
|
|
AU2020261411B2
(en)
|
2019-04-26 |
2025-10-02 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car T cells
|
|
CA3134308A1
(en)
|
2019-04-26 |
2020-10-29 |
Thomas Charles PERTEL |
Rituximab-resistant chimeric antigen receptors and uses thereof
|
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
|
WO2020223535A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
CA3138972A1
(en)
|
2019-05-04 |
2020-11-12 |
Inhibrx, Inc. |
Clec12a-binding polypeptides and uses thereof
|
|
JP7741732B2
(ja)
*
|
2019-05-07 |
2025-09-18 |
グレイセル・バイオテクノロジーズ（シャンハイ）カンパニー・リミテッド |
Ｂｃｍａを標的とする操作された免疫細胞及びその使用
|
|
CN113784733B
(zh)
*
|
2019-05-07 |
2024-09-06 |
亘喜生物科技（上海）有限公司 |
靶向bcma的工程化免疫细胞及其用途
|
|
KR20220031549A
(ko)
|
2019-05-08 |
2022-03-11 |
2세븐티 바이오, 인코포레이티드 |
Cll-1 표적화 면역요법
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US20220226464A1
(en)
|
2019-05-28 |
2022-07-21 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
US20220220504A1
(en)
|
2019-05-28 |
2022-07-14 |
Miltenyi Biotec B.V. & Co. KG |
Method for Generation of Genetically Modified T Cells
|
|
WO2020257823A2
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
TGF-β RECEPTORS AND METHODS OF USE
|
|
JP2022541320A
(ja)
*
|
2019-07-24 |
2022-09-22 |
エウレカ セラピューティクス インコーポレイテッド |
キメラ抗原受容体ｔ細胞及びその使用
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021047804A1
(en)
|
2019-09-11 |
2021-03-18 |
Miltenyi Biotec B.V. & Co. KG |
In vitro method for transduction of t cells in the presence of malignant cells
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
AU2020362554A1
(en)
*
|
2019-10-08 |
2022-05-12 |
Provincial Health Services Authority |
Chimeric cytokine receptors
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US20230053013A1
(en)
*
|
2019-12-03 |
2023-02-16 |
University Of Massachusetts |
Compositions and methods for optogenetic immunotherapy
|
|
CN113087805A
(zh)
*
|
2019-12-31 |
2021-07-09 |
华东师范大学 |
一种共表达免疫调节分子的嵌合抗原受体t细胞的制备及其应用
|
|
KR20220128650A
(ko)
*
|
2020-01-13 |
2022-09-21 |
엔카르타, 인크. |
Bcma-유도된 세포 면역요법 조성물 및 방법
|
|
WO2021150919A1
(en)
|
2020-01-23 |
2021-07-29 |
The Children's Medical Center Corporation |
Stroma-free t cell differentiation from human pluripotent stem cells
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
US20230100000A1
(en)
|
2020-02-04 |
2023-03-30 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
|
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
|
CN115427451A
(zh)
*
|
2020-02-14 |
2022-12-02 |
北京永泰瑞科生物科技有限公司 |
过表达从外部导入的细胞信号调节因子的免疫细胞及其用途
|
|
JP7781761B2
(ja)
|
2020-02-27 |
2025-12-08 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
CN115175695A
(zh)
|
2020-02-27 |
2022-10-11 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
CA3171066A1
(en)
|
2020-03-11 |
2021-09-16 |
Saar GILL |
Methods and composition for gene delivery using an engineered viral particle
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN115397517A
(zh)
|
2020-04-17 |
2022-11-25 |
希望之城 |
用于治疗flt3阳性恶性肿瘤的靶向flt3的嵌合抗原受体修饰细胞
|
|
EP3916388A1
(en)
|
2020-05-27 |
2021-12-01 |
Miltenyi Biotec B.V. & Co. KG |
Reagents for detection of chimeric antigen receptor cells
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
IL298510A
(en)
|
2020-06-12 |
2023-01-01 |
Nkarta Inc |
Genetically modified natural killer cells for cd70-directed cancer immunotherapy
|
|
WO2021258016A1
(en)
|
2020-06-19 |
2021-12-23 |
Fate Therapeutics, Inc. |
Combining ipsc-derived effector cell types for immunotherapy use
|
|
CN116234558A
(zh)
|
2020-06-26 |
2023-06-06 |
朱诺治疗学有限公司 |
条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
|
|
MX2023002041A
(es)
*
|
2020-08-20 |
2023-04-27 |
A2 Biotherapeutics Inc |
Composiciones y métodos para tratar cánceres positivos para mesotelina.
|
|
EP3964585A1
(en)
|
2020-09-03 |
2022-03-09 |
Miltenyi Biotec B.V. & Co. KG |
Cd62l specific lentiviral vector particle for targeted transduction of t cell subsets
|
|
CA3191588A1
(en)
|
2020-09-04 |
2022-03-10 |
Bettina KOTTER |
System for inducible expression of an adapter in immune cells
|
|
IL302396A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
CN116635062A
(zh)
|
2020-11-13 |
2023-08-22 |
诺华股份有限公司 |
使用表达嵌合抗原受体（car）的细胞的组合疗法
|
|
AU2021386370A1
(en)
|
2020-11-24 |
2023-06-22 |
Lyell Immunopharma, Inc. |
Methods for making, compositions comprising, and methods of using rejuvenated t cells
|
|
IL303270A
(en)
|
2020-12-21 |
2023-07-01 |
Allogene Therapeutics Inc |
The CD45–GATE vehicle activates a protease
|
|
JP2024505248A
(ja)
*
|
2021-01-29 |
2024-02-05 |
アウトペース バイオ インコーポレイテッド |
小分子によって調節される細胞シグナル伝達発現システム
|
|
US20240115608A1
(en)
*
|
2021-02-10 |
2024-04-11 |
The Regents Of The University Of California |
Immune receptors with synthetic co-stimulatory domains
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
GB202104030D0
(en)
*
|
2021-03-23 |
2021-05-05 |
Autolus Ltd |
Signalling system
|
|
US20240180969A1
(en)
*
|
2021-04-01 |
2024-06-06 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting hla-a*11 and methods of use thereof
|
|
WO2022241235A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
GB202108366D0
(en)
|
2021-06-11 |
2021-07-28 |
Quell Therapeutics Ltd |
Multichain chimeric antigen receptor
|
|
EP4376876A1
(en)
|
2021-07-26 |
2024-06-05 |
Kite Pharma, Inc. |
Split chimeric antigen receptors and methods of use
|
|
WO2023044304A1
(en)
*
|
2021-09-15 |
2023-03-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
|
|
US20250235477A1
(en)
|
2021-10-06 |
2025-07-24 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
CR20240195A
(es)
|
2021-10-14 |
2024-06-20 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnhc coexpresados y sistemas de compuerta lógica
|
|
WO2023062113A1
(en)
|
2021-10-15 |
2023-04-20 |
Miltenyi Biotec B.V. & Co. KG |
Method for the generation of genetically modified nk cells
|
|
WO2023130462A1
(zh)
*
|
2022-01-10 |
2023-07-13 |
卡瑞济(北京)生命科技有限公司 |
靶向IL13Rα2的嵌合抗原受体及其用途
|
|
CN114736306B
(zh)
*
|
2022-03-01 |
2024-04-19 |
中国科学院深圳先进技术研究院 |
一种受化学调控的蛋白酶工具及其配套底物
|
|
CN118973608A
(zh)
|
2022-04-01 |
2024-11-15 |
美天施生物科技有限两合公司 |
用于多核苷酸的药物诱导型表达的系统
|
|
CA3247010A1
(en)
|
2022-04-08 |
2023-10-12 |
Ono Pharmaceutical Co |
CHIMERIC ANTIGEN RECEPTOR FOR TUMOR TARGETING
|
|
CN119256075A
(zh)
|
2022-04-08 |
2025-01-03 |
菲特治疗公司 |
具有实体瘤靶向骨架的细胞及其用途
|
|
US20250295773A1
(en)
|
2022-05-10 |
2025-09-25 |
Miltenyi Biotec B.V. & Co. KG |
Compositions comprising il-15, il-15 receptor alpha and the intracellular signaling domain of cd2 for immune cell therapy
|
|
US20250313815A1
(en)
*
|
2022-05-13 |
2025-10-09 |
Northwestern University |
Active loading of cargo entity into lipid bilayer particles using dimerization domains
|
|
EP4526332A1
(en)
|
2022-05-16 |
2025-03-26 |
Miltenyi Biotec B.V. & Co. KG |
Endogenous signaling molecule activating chimeric antigen receptors and methods of generation thereof
|
|
WO2024050325A2
(en)
*
|
2022-09-01 |
2024-03-07 |
Sri International |
Genetically engineered cd4 t-cells for in situ synthesis of proteins
|
|
CN119907680A
(zh)
|
2022-09-15 |
2025-04-29 |
诺华股份有限公司 |
使用嵌合抗原受体疗法的自身免疫性障碍的治疗
|
|
EP4342488A1
(en)
|
2022-09-26 |
2024-03-27 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor specific for folate receptor 1
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
EP4602171A1
(en)
|
2022-10-15 |
2025-08-20 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
KR102834479B1
(ko)
*
|
2022-11-04 |
2025-07-16 |
한국과학기술연구원 |
형광공명에너지전이 기반 car 활성 센싱용 바이오센서 및 그의 용도
|
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024158800A2
(en)
*
|
2023-01-24 |
2024-08-02 |
Ginkgo Bioworks, Inc. |
Immune cell stimulatory sequences
|
|
WO2024182539A1
(en)
|
2023-02-28 |
2024-09-06 |
Lyell Immunopharma, Inc. |
Methods of culturing reprogrammed cells
|
|
KR20250131823A
(ko)
|
2023-03-31 |
2025-09-03 |
아벨제타 인크. |
Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체
|
|
WO2024223847A1
(en)
|
2023-04-27 |
2024-10-31 |
Miltenyi Biotec B.V. & Co. KG |
Pseudotyped retroviral vector particle with anti-cd3 display
|
|
WO2024223870A1
(en)
|
2023-04-27 |
2024-10-31 |
Miltenyi Biotec B.V. & Co. KG |
Retroviral vector particle pseudotyped with envelope proteins of canine distemper virus
|
|
EP4470555A1
(en)
|
2023-05-31 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
Anti-tag chimeric antigen receptors with specificity for mutated peptides derived from human fgfr2
|
|
EP4471067A1
(en)
|
2023-06-01 |
2024-12-04 |
Miltenyi Biotec B.V. & Co. KG |
A chemically inducible heterodimerizing system and a method for generation thereof
|
|
WO2025008108A1
(en)
|
2023-07-06 |
2025-01-09 |
Miltenyi Biotec B.V. & Co. KG |
Immune cell expressing chimeric antigen receptor and transgenic t cell receptor
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025078492A1
(en)
|
2023-10-13 |
2025-04-17 |
Miltenyi Biotec B.V. & Co. KG |
Cd3-targeted nipah-pseudotyped lentiviral vector particles
|
|
EP4545963A1
(en)
|
2023-10-26 |
2025-04-30 |
Miltenyi Biotec B.V. & Co. KG |
Method for selecting antigen recognizing moieties having specificity for a target structure
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025224123A1
(en)
|
2024-04-25 |
2025-10-30 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptors specific for fibroblast activation protein
|